前脑Ank2的早期发育删除会通过重塑突触蛋白质组,导致与有关的表型
Sehyoun Yoon1, Marc Dos Santos1, Marc P Forrest1
1Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Cell reports
|July 10, 2023
概括
安基林-B (ANK2) 的遗传变异会导致神经发育障碍. 在小鼠中产前缺失会导致发作和社会缺陷,与改变的突触蛋白和神经元过激动性有关.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 编码安基林-B的ANK2中的罕见遗传变异与神经发育障碍 (NDD) 有关.
- 与ANK2相关的NDDs背后的精确致病机制在很大程度上是未知的.
- 了解安基林-B的作用对于破译NDD的病原性至关重要.
研究的目的:
- 调查安基林-B在神经发育中的作用及其对NDD的贡献.
- 阐明ANK2在大脑中丧失的分子和细胞后果.
- 确定ANK2相关的NDD的潜在治疗点.
主要方法:
- 在特定的神经元群体中生成具有产前或青少年ANK2缺失的条件淘汰小鼠模型.
- 行为评估包括发作监测,死亡率跟踪,多动症和社交互动测试.
- 皮层神经元活动的体内和体外电生理学记录 (成像).
- 对突触膜的定量蛋白质组分析和安基林-B相互作用组研究.
- 使用AMPA受体抗剂 (佩拉曼内尔) 的药理干预.
主要成果:
- 在皮层激发性神经元和寡类细胞 (Ank2-/-:Emx1-Cre) 中ANK2的产前缺失导致严重的自发性发作,死亡率增加,过度活跃以及社会缺陷.
- 前脑刺激神经元 (Ank2-/-:CaMKIIα-Cre) 的青少年缺失没有产生这些表型,这表明产前安基林-B的关键作用.
- 成像显示神经元事件幅度和频率增加,这表明Ank2-/-:Emx1-Cre小鼠的网络过激和过同步.
- 蛋白质组分析显示,皮层突触膜中调节树突脊柱可塑性的蛋白质和中间丝的水平发生了变化.
- 安基林-B相互作用组包括与自闭症和风险因素相关的蛋白质.
- 在Ank2-/-:Emx1-Cre小鼠中,佩拉曼奈尔部分挽救了生存,并恢复了皮质神经元活动.
结论:
- 在特定的大脑细胞中产前失去了安基林-B,破坏了神经元活动和网络同步.
- 突触蛋白质组的变化,特别是与可塑性相关的蛋白质的变化,有助于观察到与NDD相关的行为障碍.
- 向AMPA受体功能可能为ANK2相关的神经发育障碍提供治疗策略.
相关概念视频
Arteries of the Lower Limbs
215
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
215
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
349
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
349


